Publication Date
1-1-2022
Journal
Practical Laboratory Medicine
DOI
10.1016/j.plabm.2021.e00261
PMID
34977312
PMCID
PMC8710236
PubMedCentral® Posted Date
12-26-2021
PubMedCentral® Full Text Version
Post-print
Published Open-Access
yes
Keywords
COVID, SARS-CoV-2, Vaccine, Serology, Antibody, Employee
Abstract
To gain insights on the heterogeneity of immune responses to vaccination against SARS-CoV-2 and to identify factors that could make individuals vulnerable to infection due to lack of response to vaccination, our hospital started offering free voluntary post-antibody testing against the spike protein IgG for all fully vaccinated employees.
Post-vaccination response against SARS-CoV-2 was assessed using the FDA-EUA approved VITROS anti-SARS-CoV-2 IgG immunometric assay specific to the spike protein.
Out of a total of 3266 antibody tests performed in fully vaccinated Texas Children’s, 99.4% had a positive antibody response to the spike protein. From the 21 employees (0.6%) that had a negative response, 66.7% reported taking immunosuppressive drugs and/or biologics.
Our data shows that most of the employees tested at our institution mounted an immune response to the immunogen in the vaccine. Post-vaccination antibody testing against SARS-CoV-2 can provide useful information to guide decisions about future vaccine doses.
Included in
COVID-19 Commons, Epidemiology Commons, Health and Medical Administration Commons, Immunology of Infectious Disease Commons, Immunopathology Commons, Medical Immunology Commons, Pathology Commons, Pediatrics Commons